Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 3/20 | 0.45 |
| ▸ | ARG2 | P78540 | 2/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 4/20 | 0.41 |
| ▸ | GRM6 | O15303 | 3/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1632919 | 0.98 | ARG1 (0.44) | ARG1ARG2GRM2GRM3GRM6 | |
| SCHEMBL2899251 | 0.94 | GRM2 (0.40) | ARG1ARG2GRM2GRM3GRM6 | |
| SCHEMBL10392022 | 0.94 | GRM2 (0.40) | ARG1ARG2GRM2GRM3GRM6 | |
| Hydrochloric Acid SCHEMBL3129049 | 0.92 | ARG1 (0.39) | ARG1ARG2GRM2GRM3GRM6 | |
| SCHEMBL13472248 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL14676591 | 0.84 | GRM2 (0.47) | ARG1GRM2GRM3GRM6GRM8 | |
| SCHEMBL16594983 | 0.77 | EPHX1 (0.38) | ARG1ARG2 | |
| SCHEMBL20543419 | 0.76 | GRM6 (0.41) | ARG1ARG2GRM2GRM3GRM6 | |
| SCHEMBL8443472 | 0.76 | ARG1 (0.46) | ARG1ARG2GRM2GRM3GRM6 | |
| SCHEMBL7752047 | 0.76 | GRM2 (0.47) | ARG1ARG2GRM2GRM3GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | claimed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| US-8269046-B2 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY, LLC (US) | 2012-09-18 | — | — | US | disclosed |
| EP-1631633-B1 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | ARIZONA CHEM (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100064933-A1 | Cyclic Bisamides Useful in Formulating Inks for Phase-Change Printing | ARIZONA CHEMICAL COMPANY LLC | 2010-03-18 | — | — | US | disclosed |
| US-20060128992-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1631633-A2 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | Arizona Chemical Company (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6960248-B2 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2004106442-A2 | CYCLIC BISAMIDES USEFUL IN FORMULATING INKS FOR PHASE-CHANGE PRINTING | ARIZONA CHEMICAL COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040231555-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | ARIZONA CHEMICAL COMPANY | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | ARG1 229/4885ARG2 316/4885GRM2 2853/4885 |
| US-20060128992-A1 | Cyclic bisamides useful in formulating inks for phase-change printing | FHIT, DDC, MNAT1 | ARG1 1045/4885ARG2 889/4885GRM2 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.